AXIM Biotechnologies, Inc., a diagnostic and biotechnology company focused on ocular and inflammatory diseases, announced the engagement of 624 Advisors, owned and managed by Dr. Alan J. Touch, as Chief Medical & Regulatory Affairs Advisor. This strategic move comes at a pivotal stage in the company's development as it prepares for key regulatory submissions and commercial expansion.
Dr. Touch brings more than three decades of global leadership across diagnostics, medical devices, pharmaceuticals, and digital health. He is the original co-inventor of the first ocular diagnostic technologies acquired by AXIM and inventor of the world's first colored contact lens. His extensive background includes former leadership roles at Bausch & Lomb and as Principal Strategist for Ophthalmology, Medical Devices and Diagnostics at INC Research (Syneos Health).
The importance of this appointment lies in Dr. Touch's unique combination of inventor-level knowledge of AXIM's technology with significant senior-level experience in FDA regulation, ISO quality systems, clinical development, and manufacturing readiness. His involvement is designed to strengthen AXIM's regulatory strategy, quality foundation, and clinical execution while positioning the company for efficient global expansion and long-term operational scale.
Catalina Valencia, President and CEO of AXIM Biotechnologies, emphasized the strategic value of this engagement, stating that Dr. Touch's background uniquely aligns with AXIM's current efforts and upcoming goals. The company is advancing toward key regulatory and commercial milestones, including upcoming FDA 510(k) submissions, international regulatory expansion, and the establishment of a robust quality and manufacturing infrastructure. For more information about AXIM's diagnostic technologies, visit https://www.aximbiotech.com.
Dr. Touch's specific expertise includes deep experience across FDA, EU MDR/IVDR, and global regulatory frameworks, proven leadership in regulatory affairs, quality systems, clinical development, and manufacturing scale-up. His engagement is expected to reduce AXIM's reliance on external consultants and accelerate readiness for commercialization and global growth.
"I am pleased to work with AXIM at this important stage and to continue advancing technology I originally helped develop," said Dr. Alan J. Touch. He noted that AXIM is building a strong foundation for market-sensitive regulatory excellence and clinical credibility for its products. The original press release can be viewed on https://www.newmediawire.com.
For the diagnostic and biotechnology industry, this appointment signals AXIM's commitment to strengthening its regulatory capabilities as it prepares for market entry. The engagement of a regulatory specialist with Dr. Touch's credentials suggests the company is taking a methodical approach to navigating complex global regulatory environments, which could serve as a model for other emerging biotech companies seeking to bring innovative diagnostic solutions to market.
